Effective October 23, 2020, the Board of Directors of Cure Pharmaceutical Holding Corp. (the “Company”), appointed Nancy Duitch as a new member of the Board pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 23, 2020 (the “Merger Agreement”), by and among the Company, Cure Labs Inc., and The Sera Labs Inc., and Nancy Duitch, in her capacity as the security holders representative. On October 5, 2020, as a condition to closing the Merger, the Company entered into an employment agreement with Ms. Duitch as Chief Strategy Officer-Wellness of the Company.